BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21739480)

  • 21. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
    Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer.
    Popanda O; Schattenberg T; Phong CT; Butkiewicz D; Risch A; Edler L; Kayser K; Dienemann H; Schulz V; Drings P; Bartsch H; Schmezer P
    Carcinogenesis; 2004 Dec; 25(12):2433-41. PubMed ID: 15333465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single nucleotide polymorphisms in tobacco metabolism and DNA repair genes and prognosis in resected non-small-cell lung cancer.
    Campayo M; ViƱolas N; Navarro A; Carcereny E; Casas F; Gel B; Diaz T; Gimferrer JM; Marrades RM; Ramirez J; Monzo M
    J Surg Res; 2011 May; 167(1):e5-12. PubMed ID: 21324488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer.
    Liu L; Wu J; Zhong R; Wu C; Zou L; Yang B; Chen W; Zhu B; Duan S; Yu D; Tan W; Nie S; Lin D; Miao X
    Mol Carcinog; 2013 Dec; 52(12):923-31. PubMed ID: 22821704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis.
    Kiyohara C; Takayama K; Nakanishi Y
    Lung Cancer; 2006 Dec; 54(3):267-83. PubMed ID: 16982113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population.
    Hu Z; Xu L; Shao M; Yuan J; Wang Y; Wang F; Yuan W; Qian J; Ma H; Wang Y; Liu H; Chen W; Yang L; Jing G; Huo X; Chen F; Jin L; Wei Q; Wu T; Lu D; Huang W; Shen H
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1336-40. PubMed ID: 16835333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese.
    Dai J; Hu Z; Dong J; Xu L; Pan S; Jiang Y; Jin G; Chen Y; Shen H
    Int J Cancer; 2012 Feb; 130(3):671-6. PubMed ID: 21412764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck.
    An J; Liu Z; Hu Z; Li G; Wang LE; Sturgis EM; El-Naggar AK; Spitz MR; Wei Q
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1633-8. PubMed ID: 17684138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy.
    Yoon SM; Hong YC; Park HJ; Lee JE; Kim SY; Kim JH; Lee SW; Park SY; Lee JS; Choi EK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):885-91. PubMed ID: 16199318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
    Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
    Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
    Zheng Y; Deng Z; Yin J; Wang S; Lu D; Wen X; Li X; Xiao D; Hu C; Chen X; Zhang W; Zhou H; Liu Z
    Int J Cancer; 2017 Dec; 141(11):2336-2347. PubMed ID: 28791697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer.
    Kim M; Kang HG; Lee SY; Lee HC; Lee EB; Choi YY; Lee WK; Cho S; Jin G; Jheon HS; Son JW; Lee MH; Jung DK; Cha SI; Kim CH; Kang YM; Kam S; Jung TH; Jheon S; Park JY
    Cancer Sci; 2010 Nov; 101(11):2436-42. PubMed ID: 20731661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.
    Li D; Zhou Q; Liu Y; Yang Y; Li Q
    Med Oncol; 2012 Sep; 29(3):1622-8. PubMed ID: 21805378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.